Sandy Wong, MD, discusses investigational CAR T-cell products in relapsed/refractory multiple myeloma.
Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses investigational CAR T-cell products in relapsed/refractory multiple myeloma.
One candidate is the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel (ide-cel; bb2121), which demonstrated an overall response rate (ORR) of 73.4% and a median progression-free survival of 8.6 months in patients with relapsed/refractory disease in the phase II KarMMA trial.
JNJ-4528, another BCMA-targeted product, achieved a 100% ORR in the phase Ib/II CARTITUDE-1 trial in patients with heavily pretreated relapsed/refractory multiple myeloma. These results supplement data from the Chinese LEGEND-2 study (NCT03090659) which is investigating the same product in a slightly different patient population.
These data indicate that moving CAR T-cell therapy to an earlier line of treatment may enhance response for patients, concludes Wong.